Specialty pharmaceutical company Yaupon Therapeutics Inc., of Malvern, said it raised $14.4 million in a private placement of preferred stock.
Yaupon is privately held.
Investors in the new round include prior investors Vivo Ventures, Palo Alto Investors and Burrill & Co., plus a new investor, Aperture Venture Partners, Yaupon said.
The company is developing a topical treatment for early stage mycosis fungoid's, the most common type of cutaneous T-cell lymphoma. - Reid Kanaley
